Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.

PP405 was ineffective for hair growth as some follicles were already active before treatment, raising doubts about its efficacy. Users discussed other hair loss treatments like Minoxidil, finasteride, and RU58841, expressing skepticism and hope for future solutions.

The user has been using finasteride for over two years with mixed results and is considering starting dutasteride and oral minoxidil, though both are hard to obtain. They are also contemplating a hair transplant in the future due to diffuse thinning.

RU58841 shows the strongest results despite weaker binding affinity, while KX-826 and CB-03-01 are more expensive and have minimal side effects. RU58841 is considered effective but has potential health risks if ingested; users report positive outcomes with RU58841 and finasteride.

Pelage Pharmaceuticals' PP405 is discussed with skepticism about its effectiveness in hair regrowth, with some users expressing doubt and others hopeful but cautious. Treatments like finasteride are mentioned as current options, but there's a general sentiment that a cure for hair loss is not imminent.

A 19-year-old plans to use an experimental hair loss treatment stack including micro-needling, Minoxidil, Pyrilutamide, Ketoconazole shampoo, and other unreleased compounds like PP405. Users advise against using unverified treatments and suggest sticking to proven options like Finasteride, with some recommending topical application to avoid side effects.

A 27-year-old male experienced significant hair regrowth in two months using a daily oral 3-in-1 pill containing 1.1mg finasteride, 5mg minoxidil, and 1mg biotin from LockLab, with no side effects reported. The user also uses a derma-stamp twice a week to promote blood flow and stimulate growth.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

A user experienced significant hair improvement using oral finasteride for six months, adding microneedling and switching to non-sulfate shampoo. They managed side effects by working out and noticed no negative impact on libido.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

A 19-year-old experiencing hair loss despite using minoxidil and finasteride for three months, with no family history of baldness except for maternal grandfather. The user is advised to continue the treatment for Androgenic Alopecia and not rely on home remedies.

The user has been using 1.25 mg of finasteride daily since June 2024 to promote hair regrowth and thickness, considering switching to dutasteride if results are unsatisfactory. They are hesitant to add minoxidil due to cost and potential side effects but have seen some progress with finasteride alone.

User shared 16-month progress using finasteride 1 mg/day and minoxidil 5% solution once/day, noting significant regrowth, especially in temporal peaks. Users discussed shedding, side effects, and positive feedback from others.

A 28-year-old underwent three hair transplants totaling 11,102 grafts at Eugenix, using finasteride and minoxidil to manage advanced hair loss. Despite limited density, the results are satisfactory, allowing the individual to feel presentable without a hat.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

An 18/19-year-old male started balding at 16 and initially saw hair growth with minoxidil, but results diminished over time. He switched dermatologists and is now using a regimen of topical finasteride, minoxidil, vitamin D, and supplements, hoping for better results.

The conversation discusses severe hair shedding and thinning, with the original poster using finasteride, oral minoxidil, and other supplements without improvement. The discussion highlights the possibility of telogen effluvium and the importance of addressing potential underlying health issues, such as stress and gut health, rather than assuming diffuse unpatterned alopecia (DUPA).

A 23-year-old shares their 5-month progress using oral finasteride and minoxidil for hair loss, noting initial reduced shedding and later thicker hair shedding. Users reassure that multiple sheds are normal and indicate progress.

A 26-year-old male shares his hair loss journey, using finasteride and fish oil daily since the pandemic. He briefly tried biotin and microneedling but stopped due to inconvenience.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.

The conversation discusses hair loss treatments, specifically using finasteride pills, RU58841 topically, and dermarolling twice a week. The user also mentions considering minoxidil and addressing a vitamin D deficiency, which may have contributed to reduced hair shedding.

The user has been using 1mg finasteride and 2.5mg oral minoxidil for three months, noticing new blonde hairs but experiencing ongoing shedding. They also use GHK-Cu, which has improved skin but not hair.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

The user is experiencing significant hair shedding despite using 1.25mg oral minoxidil and 1mg finasteride daily for a year. They are advised to monitor health factors like vitamin levels and heart health, and consider increasing ferritin levels for optimal hair growth.

A user shared their experience using 5% minoxidil twice daily, 1 mg finasteride daily, and weekly derma stamping for hair loss, noting no crown thinning but front diffuse thinning and hairline issues. They experienced fewer side effects on 0.5 mg finasteride but returned to 1 mg, and did not experience shedding after starting treatment.